Depósito Digital de Documentos de la UAB Encontrados 3 registros  La búsqueda tardó 0.01 segundos. 
1.
9 p, 1.0 MB HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma / Maroto Rey, José Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Esteban, E. (Department of Oncology, Nuevo HUCA, Oviedo) ; Parra, E Fernández (Department of Oncology, H. U. Nuestra Señora de Valme, Sevilla) ; Mendez-Vidal, MJ (Department of Oncology, H. U. Reina Sofía, Córdoba) ; Domenech, M (Department of Oncology, Hospital de Althaia Xarxa Asistencial Manresa, Barcelona) ; Pérez-Valderrama, B (Department of Oncology, H. U. Virgen del Rocio, Sevilla) ; Calderero, V (Department of Oncology, H. Fundación Miguel Servet, Zaragoza) ; Pérez-Gracia, JL (Department of Oncology, Clinica Universitaria de Pamplona, Pamplona) ; Grande, E (Department of Oncology, H. Ramón y Cajal, Madrid) ; Algaba, Ferran (Institut d'Investigació Biomèdica Sant Pau)
Clear-cell renal cell carcinoma (ccRCC) is a heterogeneous disease with a different clinical behavior and response to targeted therapies. Differences in hypoxia-inducible factor (HIF) expression have been used to classify von Hippel-Lindau gene (VHL)-deficient ccRCC tumors. [...]
2017 - 10.2147/OTT.S137677
OncoTargets and therapy, Vol. 10 (september 2017) , p. 4635-4643  
2.
8 p, 223.4 KB Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia / Ribera, Josep-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ferrer, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. [...]
2015 - 10.2147/OTT.S70524
OncoTargets and therapy, Vol. 8 (june 2015) , p. 1567-1574  
3.
8 p, 215.1 KB Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer / Muñoz-Couselo, Eva (Hospital Universitari Vall d'Hebron) ; Pérez-García, José (Hospital Universitari Vall d'Hebron) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient's duration and quality of life. Treatment options for MBC have become more efficacious and numerous. [...]
2011 - 10.2147/OTT.S16392
OncoTargets and therapy, Vol. 4 (november 2011) , p. 185-192  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.